Developer docs
API playgroundTry for free, no card

Search company profiles

Alix Ventures

Full company profile

uuid0007ar2

Namestring
Alix Ventures
Legal namestring
Alix Ventures
Websiteurl
alix.vc
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Alix Ventures is an early-stage venture capital firm founded in 2020 and headquartered in the San Francisco Bay Area, focused on backing TechBio startups at the intersection of technology and biology that target radical advances in human health. The firm invests at Pre-Seed, Seed, and select Series A stages with $100K-$500K check sizes, reserving 50% of fund capital for follow-on investments of $1-2M (Series A) and $5-10M (Series B). Alix serves early-stage Life Science founders building both therapeutic/diagnostic applications and bio-economy infrastructure, with portfolio companies spanning cell and gene therapy (64x Bio, Strand Therapeutics, Exthymic), synthetic biology (Elegen, Chemify), ADCs (Mythic Therapeutics), precision immunology (Endpoint Health), organoids (Xilis), single-cell platforms (Zafrens), mass cytometry (Teiko), and digital health (Pair Team).

The firm's core proprietary asset is the BIOS Platform — an integrated ecosystem of content (BIOS Medium publication ranked Top VC Writer, BIOS Podcast ranked Top 100 Life Sciences, BIOS Daily Newsletter with 25K+ subscribers), community (BIOS Commons with 1000+ invite-only members), and capital (BIOS Angels, the world's first TechBio angel syndicate). This ecosystem functions as a deal-sourcing and brand-building engine, augmented by a Venture Residency Program that admits 2 fellows per year from 4000+ applicants (~0.1% acceptance rate) with a 100% placement rate into top-tier VC firms and startups. The team consists of 1-10 employees led by Founder & General Partner Chas Pulido (ex-Pareto Life Sciences, Clara Health, Liquid 2 Ventures), Venture Partner Nick Goldner (PhD, founder of Viosera Therapeutics and resistanceBio), and Operating Partner Mark Pulido (former CEO of Novartis Pharmaceuticals USA, McKesson, and ABILITY). Scientific Advisory Board members include Brian Fiske (co-founder/CSO Mythic Therapeutics), Daniel Delubac (COO Xilis), and Jake Becraft (co-founder/CEO Strand Therapeutics).

Alix's revenue model is that of a traditional venture capital fund: management fees on committed capital (typically 2%) plus carried interest on portfolio exits (typically 20%), with no fees charged to portfolio companies for investment. The firm has co-invested alongside tier-1 funds including a16z, Foresite Capital, Viking Global, First Round, Mayfield, 8VC, KdT, Founders Fund, HOF Capital, Northpond, Mubadala, GV, LSP, Felicis, and Two Sigma. Portfolio companies have collectively raised $850M+ in capital and reached a $2.5B+ aggregate valuation, creating 700+ jobs across the portfolio. Alix's go-to-motion is community-led content marketing at the top of the funnel (BIOS content and community), followed by a structured 3-meeting investment process over 3-4 weeks for diligence and decision-making.

Short descriptiontext

Alix Ventures is an early-stage venture capital firm backing TechBio startups at Pre-Seed, Seed, and Series A stages with $100K-$500K checks, operating the BIOS ecosystem (community, content, and angel syndicate) to source deals and support Life Science founders driving patient impact.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, early stage funding, life sciences investing, TechBio startups, angel syndicate
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAI
Micro-VC & Angel Funds
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Life Science Venture Capital
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns / Portfolio Equity
TypeSubscription Recurring
Description

Alix Ventures generates returns through equity ownership in early-stage Life Science portfolio companies. As a VC firm, revenue is realized through exits (acquisitions, IPOs) of portfolio companies. The firm reserves 50% of its fund for follow-on investments and targets $1–2M SPVs for Series As and $5–10M for Series Bs, indicating significant capital reserved to maintain/increase ownership through subsequent rounds.

alix.vc
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
Pricing details3 tiers
1Seed Investment: $100K–$500K per company
ModelOtherBilling cadenceMulti-year contract
Notes

Check size tailored to the size and nature of the round. Alix is happy to be first check in and help syndicate rounds with its large network of co-investors.

alix.vc
2Follow-on Reserve: 50% of fund for portfolio companies
ModelOtherBilling cadenceMulti-year contract
Notes

Capital reserved for follow-on rounds; SPVs of $1–2M for Series A, $5–10M for Series B.

alix.vc
3Venture Fellowship Stipend: $5,000 for 1-year part-time program
ModelOtherBilling cadenceAnnual
Notes

Remote, part-time (~15 hours/week), 1-year duration. Rolling admissions year-round. Position titled 'Venture Resident'.

alix.vc
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BIOS
Description

Content and community platform for Life Science startup innovation. Includes BIOS Medium, BIOS Podcast, BIOS Daily Newsletter, BIOS Angels (angel investing syndicate), and BIOS Commons (invite-only community with 1000+ members).

alix.vc
Core offering1 text field

Alix Ventures provides Pre-Seed, Seed, and selective Series A equity investments ($100K–$500K initial checks) to early-stage Life Science and TechBio startups, reserving 50% of fund capital for follow-on participation in $1–2M Series A and $5–10M Series B SPVs. Portfolio companies receive value-add services including customer introductions, fundraising support, hiring assistance, KPI guidance, and access to the BIOS ecosystem (BIOS Commons community of 1000+ members, BIOS Angels syndicate, BIOS Medium, BIOS Podcast, BIOS Daily Newsletter with 25K+ subscribers) along with operating support from a 5x CEO Operating Partner.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Portfolio companies have raised $850M+ in total capital and created 700+ jobs with a collective portfolio value exceeding $2.5B.
+3 more records
Product overview1 text field

Alix Ventures is an early-stage Life Science venture capital firm that operates as a unified platform combining investment services with community and content products. The core offering centers on BIOS, a comprehensive TechBio ecosystem comprising BIOS Community (1000+ member invite-only network), BIOS Angels (world's first TechBio angel syndicate), BIOS Medium (top VC writer content platform), BIOS Podcast (top 100 podcast), and BIOS Daily Newsletter (25K+ subscribers). These products work together to unite Life Science innovators, facilitate investment opportunities, and drive patient impact. Alix also offers a Venture Residency Program for aspiring VC professionals and produces thematic research reports covering frontier biotechnology areas. The firm's investment portfolio spans 18+ companies including Xilis, Elegen, 64x Bio, Mythic, Endpoint Health, Zafrens, Teiko, and others focused on cell therapy, gene therapy, synthetic biology, and precision medicine.

Product and service8 records
1Pre-Seed, Seed, and Series A Venture Capital Investments
CategoryVenture Capital Investment
Description

Equity capital investments of $100K–$500K at Pre-Seed, Seed, and select Series A stages for early-stage Life Science and TechBio startups, typically as first institutional check-in, with follow-on capital reserved for portfolio companies.

2BIOS Community
CategoryCommunity Platform
Description

An invite-only community platform (BIOS Commons with 1000+ members) connecting Life Science startup innovators with mentors, industry experts, and investors to foster innovation and drive patient impact.

3BIOS Angels
CategoryAngel Syndicate
Description

The world's first TechBio angel investing syndicate, enabling angel investors to participate in early-stage Life Science startup investments alongside the firm's portfolio.

4BIOS Medium
CategoryContent Platform
Description

A thought leadership content platform (Top VC Writer on Medium) featuring articles, founder spotlights, and industry insights for the Life Science ecosystem.

5BIOS Podcast
CategoryPodcast
Description

A top-ranked podcast (Top 100 Life Sciences on Spotify) featuring interviews with Life Science industry leaders covering biotechnology, healthcare innovation, and startup ecosystems.

6BIOS Daily Newsletter
CategoryNewsletter
Description

A daily newsletter with 25K+ subscribers delivering insights, news, and analysis on the evolving Life Science startup ecosystem.

7Venture Residency Program
CategoryFellowship Program
Description

A 1-year paid part-time (~15 hours/week) residency program for aspiring Life Science VC professionals and biotech entrepreneurs, offering a $5,000 stipend and reporting a 100% placement rate into VC and startup roles upon completion.

8Thematic Research Reports
CategoryResearch Content
Description

In-depth market research reports covering 18+ TechBio focal areas including Cell & Gene Therapy, Synthetic Biology, AI-Enabled Drug Discovery, CRISPR Therapeutics, Organoids, Viral Vector Manufacturing, Gene Circuits, Precision Immunology, Antibodies, ADCs, Protein Degradation, Circular RNA, Non-Viral Gene Delivery, and Spatial Transcriptomics.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of 60+ hospital clinical partnerships supporting Endpoint Health's data-driven precision immunology platform. Powers the biomarker and companion diagnostic development through real-world clinical data.

2Vanderbilt University Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of 60+ hospital clinical partnerships supporting Endpoint Health's platform. Contributes clinical data for biomarker discovery and precision companion diagnostic development.

alix.vc
3Harvard Wyss Institute for Biologically Inspired Engineering
Strategic tierCoreTypeStrategic or Co-development Partner
Description

64x Bio is a spinout of Harvard's Wyss Institute, co-founded by George Church. This academic partnership is the intellectual origin of the company's high-throughput discovery platform for viral vector manufacturing optimization.

alix.vc
4George Church (Harvard/MIT)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

George Church, renowned geneticist at Harvard and MIT, co-founded 64x Bio with Lex Rovner, Jeff Way, David Thompson, Pamela Silver. Church's lab at Harvard is the institutional birthplace of the company.

alix.vc
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage fund explicitly focused on TechBio at the intersection of technology and biology, investing at pre-seed/seed. Frequently co-invests alongside Alix (e.g., Elegen, Circularis) and shares the same founder-focused, scientific-bar approach.

TypeDirect peer
Description

Early-stage Life Sciences VC investing across digital health, diagnostics, and tech-enabled bio. Co-invested with Alix in Teiko and shares a similar founder-supportive, sector-specialist thesis.

TypeDirect peer
Description

Early-stage Life Sciences and healthcare VC investing at the intersection of biology and technology. Co-invested with Alix in 64x Bio and Mythic Therapeutics, with overlapping focus areas in CGT and oncology platforms.

TypeDirect peer
Description

Early-stage fund backing breakthrough scientific discoveries across life sciences, energy, and tech. Co-invested with Alix in Zafrens, with comparable pre-seed/seed check sizes and deep-tech orientation.

TypeDirect peer
Description

Early-stage venture firm with explicit focus on TechBio and frontier science companies. Co-invested with Alix in Circularis and 64x Bio; multiple Cantos team members are Alix Venture Residency alumni.

TypeDirect peer
Description

Early-stage fund focused on biotech and technology startups founded by Alix venture partner Nick Goldner prior to joining Alix. Similar seed-stage Life Sciences investment thesis.

TypeBroad incumbent
Description

Established venture firm with a significant TechBio and frontier-science practice investing across stages. Larger and more diversified than Alix, but operates in overlapping sectors (synthetic biology, neuroscience, space-bio convergence).

TypeBroad incumbent
Description

Tier-1 venture firm with a dedicated Bio + Health franchise investing across therapeutics, digital health, and TechBio. Recurring Alix co-investor in companies like Elegen and endpoint-health adjacent deals; operates at materially larger fund and check sizes.

TypeBroad incumbent
Description

Pioneering Life Sciences and physical sciences venture firm founding and building companies from inception. Represents the large, established end of the Life Sciences VC market where Alix portfolio companies graduate for Series B and beyond.

TypeRegional player
Description

Early-stage venture firm (founded by Joe Montana) where Alix founder Chas Pulido began his HC/LS investing career. Strong US focus on healthcare and consumer, with a similar pre-seed/seed orientation and overlapping founder-network reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment19 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alix Ventures

Life Science Venture Capitalalix.vc

Alix Ventures is an early-stage venture capital firm backing TechBio startups at Pre-Seed, Seed, and Series A stages with $100K-$500K checks, operating the BIOS ecosystem (community, content, and angel syndicate) to source deals and support Life Science founders driving patient impact.

What Alix Ventures does

Alix Ventures is an early-stage venture capital firm founded in 2020 and headquartered in the San Francisco Bay Area, focused on backing TechBio startups at the intersection of technology and biology that target radical advances in human health. The firm invests at Pre-Seed, Seed, and select Series A stages with $100K-$500K check sizes, reserving 50% of fund capital for follow-on investments of $1-2M (Series A) and $5-10M (Series B). Alix serves early-stage Life Science founders building both therapeutic/diagnostic applications and bio-economy infrastructure, with portfolio companies spanning cell and gene therapy (64x Bio, Strand Therapeutics, Exthymic), synthetic biology (Elegen, Chemify), ADCs (Mythic Therapeutics), precision immunology (Endpoint Health), organoids (Xilis), single-cell platforms (Zafrens), mass cytometry (Teiko), and digital health (Pair Team).

The firm's core proprietary asset is the BIOS Platform — an integrated ecosystem of content (BIOS Medium publication ranked Top VC Writer, BIOS Podcast ranked Top 100 Life Sciences, BIOS Daily Newsletter with 25K+ subscribers), community (BIOS Commons with 1000+ invite-only members), and capital (BIOS Angels, the world's first TechBio angel syndicate). This ecosystem functions as a deal-sourcing and brand-building engine, augmented by a Venture Residency Program that admits 2 fellows per year from 4000+ applicants (~0.1% acceptance rate) with a 100% placement rate into top-tier VC firms and startups. The team consists of 1-10 employees led by Founder & General Partner Chas Pulido (ex-Pareto Life Sciences, Clara Health, Liquid 2 Ventures), Venture Partner Nick Goldner (PhD, founder of Viosera Therapeutics and resistanceBio), and Operating Partner Mark Pulido (former CEO of Novartis Pharmaceuticals USA, McKesson, and ABILITY). Scientific Advisory Board members include Brian Fiske (co-founder/CSO Mythic Therapeutics), Daniel Delubac (COO Xilis), and Jake Becraft (co-founder/CEO Strand Therapeutics).

Alix's revenue model is that of a traditional venture capital fund: management fees on committed capital (typically 2%) plus carried interest on portfolio exits (typically 20%), with no fees charged to portfolio companies for investment. The firm has co-invested alongside tier-1 funds including a16z, Foresite Capital, Viking Global, First Round, Mayfield, 8VC, KdT, Founders Fund, HOF Capital, Northpond, Mubadala, GV, LSP, Felicis, and Two Sigma. Portfolio companies have collectively raised $850M+ in capital and reached a $2.5B+ aggregate valuation, creating 700+ jobs across the portfolio. Alix's go-to-motion is community-led content marketing at the top of the funnel (BIOS content and community), followed by a structured 3-meeting investment process over 3-4 weeks for diligence and decision-making.

Alix Ventures firmographics

Firmographics
Name
Alix Ventures
Legal name
Alix Ventures
Website
https://alix.vc
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Alix Ventures is an early-stage venture capital firm backing TechBio startups at Pre-Seed, Seed, and Series A stages with $100K-$500K checks, operating the BIOS ecosystem (community, content, and angel syndicate) to source deals and support Life Science founders driving patient impact.
Ownership category
akta.pro rank

Alix Ventures industry classification

Industry
Product category
Life Science Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAI
Micro-VC & Angel Funds

Keywords

  • Venture capital
  • Early stage funding
  • Life sciences investing
  • TechBio startups
  • Angel syndicate

Where Alix Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alix Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Returns / Portfolio Equity: Alix Ventures generates returns through equity ownership in early-stage Life Science portfolio companies. As a VC firm, revenue is realized through exits (acquisitions, IPOs) of portfolio companies. The firm reserves 50% of its fund for follow-on investments and targets $1–2M SPVs for Series As and $5–10M for Series Bs, indicating significant capital reserved to maintain/increase ownership through subsequent rounds.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractSeed Investment: $100K–$500K per company
OtherMulti-year contractFollow-on Reserve: 50% of fund for portfolio companies
OtherAnnualVenture Fellowship Stipend: $5,000 for 1-year part-time program

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Alix Ventures product offering

Product offering

Core offering

Alix Ventures provides Pre-Seed, Seed, and selective Series A equity investments ($100K–$500K initial checks) to early-stage Life Science and TechBio startups, reserving 50% of fund capital for follow-on participation in $1–2M Series A and $5–10M Series B SPVs. Portfolio companies receive value-add services including customer introductions, fundraising support, hiring assistance, KPI guidance, and access to the BIOS ecosystem (BIOS Commons community of 1000+ members, BIOS Angels syndicate, BIOS Medium, BIOS Podcast, BIOS Daily Newsletter with 25K+ subscribers) along with operating support from a 5x CEO Operating Partner.

Product overview

Alix Ventures is an early-stage Life Science venture capital firm that operates as a unified platform combining investment services with community and content products. The core offering centers on BIOS, a comprehensive TechBio ecosystem comprising BIOS Community (1000+ member invite-only network), BIOS Angels (world's first TechBio angel syndicate), BIOS Medium (top VC writer content platform), BIOS Podcast (top 100 podcast), and BIOS Daily Newsletter (25K+ subscribers). These products work together to unite Life Science innovators, facilitate investment opportunities, and drive patient impact. Alix also offers a Venture Residency Program for aspiring VC professionals and produces thematic research reports covering frontier biotechnology areas. The firm's investment portfolio spans 18+ companies including Xilis, Elegen, 64x Bio, Mythic, Endpoint Health, Zafrens, Teiko, and others focused on cell therapy, gene therapy, synthetic biology, and precision medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • BIOS: Content and community platform for Life Science startup innovation. Includes BIOS Medium, BIOS Podcast, BIOS Daily Newsletter, BIOS Angels (angel investing syndicate), and BIOS Commons (invite-only community with 1000+ members).

Products and services

  • Pre-Seed, Seed, and Series A Venture Capital Investments Equity capital investments of $100K–$500K at Pre-Seed, Seed, and select Series A stages for early-stage Life Science and TechBio startups, typically as first institutional check-in, with follow-on capital reserved for portfolio companies.
  • BIOS Community An invite-only community platform (BIOS Commons with 1000+ members) connecting Life Science startup innovators with mentors, industry experts, and investors to foster innovation and drive patient impact.
  • BIOS Angels The world's first TechBio angel investing syndicate, enabling angel investors to participate in early-stage Life Science startup investments alongside the firm's portfolio.
  • BIOS Medium A thought leadership content platform (Top VC Writer on Medium) featuring articles, founder spotlights, and industry insights for the Life Science ecosystem.
  • BIOS Podcast A top-ranked podcast (Top 100 Life Sciences on Spotify) featuring interviews with Life Science industry leaders covering biotechnology, healthcare innovation, and startup ecosystems.
  • BIOS Daily Newsletter A daily newsletter with 25K+ subscribers delivering insights, news, and analysis on the evolving Life Science startup ecosystem.
  • Venture Residency Program A 1-year paid part-time (~15 hours/week) residency program for aspiring Life Science VC professionals and biotech entrepreneurs, offering a $5,000 stipend and reporting a 100% placement rate into VC and startup roles upon completion.
  • Thematic Research Reports In-depth market research reports covering 18+ TechBio focal areas including Cell & Gene Therapy, Synthetic Biology, AI-Enabled Drug Discovery, CRISPR Therapeutics, Organoids, Viral Vector Manufacturing, Gene Circuits, Precision Immunology, Antibodies, ADCs, Protein Degradation, Circular RNA, Non-Viral Gene Delivery, and Spatial Transcriptomics.

Quantifiable outcome

  • Portfolio companies have raised $850M+ in total capital and created 700+ jobs with a collective portfolio value exceeding $2.5B.
  • +3 more outcomes

Companies that use Alix Ventures

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Alix Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alix Ventures partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Cleveland CliniccoreStrategic or Co-development PartnerOne of 60+ hospital clinical partnerships supporting Endpoint Health's data-driven precision immunology platform. Powers the biomarker and companion diagnostic development through real-world clinical data.
  • Vanderbilt University Medical CentercoreStrategic or Co-development PartnerOne of 60+ hospital clinical partnerships supporting Endpoint Health's platform. Contributes clinical data for biomarker discovery and precision companion diagnostic development.
  • Harvard Wyss Institute for Biologically Inspired EngineeringcoreStrategic or Co-development Partner64x Bio is a spinout of Harvard's Wyss Institute, co-founded by George Church. This academic partnership is the intellectual origin of the company's high-throughput discovery platform for viral vector manufacturing optimization.
  • George Church (Harvard/MIT)coreStrategic or Co-development PartnerGeorge Church, renowned geneticist at Harvard and MIT, co-founded 64x Bio with Lex Rovner, Jeff Way, David Thompson, Pamela Silver. Church's lab at Harvard is the institutional birthplace of the company.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Alix Ventures competitors and assessment

Company assessment

Direct peers

  • KdT Ventures: Early-stage fund explicitly focused on TechBio at the intersection of technology and biology, investing at pre-seed/seed. Frequently co-invests alongside Alix (e.g., Elegen, Circularis) and shares the same founder-focused, scientific-bar approach.
  • Civilization Ventures: Early-stage Life Sciences VC investing across digital health, diagnostics, and tech-enabled bio. Co-invested with Alix in Teiko and shares a similar founder-supportive, sector-specialist thesis.
  • Lifeforce Capital: Early-stage Life Sciences and healthcare VC investing at the intersection of biology and technology. Co-invested with Alix in 64x Bio and Mythic Therapeutics, with overlapping focus areas in CGT and oncology platforms.
  • Prime Movers Lab: Early-stage fund backing breakthrough scientific discoveries across life sciences, energy, and tech. Co-invested with Alix in Zafrens, with comparable pre-seed/seed check sizes and deep-tech orientation.
  • Cantos Ventures: Early-stage venture firm with explicit focus on TechBio and frontier science companies. Co-invested with Alix in Circularis and 64x Bio; multiple Cantos team members are Alix Venture Residency alumni.
  • Pioneer Fund: Early-stage fund focused on biotech and technology startups founded by Alix venture partner Nick Goldner prior to joining Alix. Similar seed-stage Life Sciences investment thesis.

Broad incumbents

  • Lux Capital: Established venture firm with a significant TechBio and frontier-science practice investing across stages. Larger and more diversified than Alix, but operates in overlapping sectors (synthetic biology, neuroscience, space-bio convergence).
  • Andreessen Horowitz (a16z Bio + Health): Tier-1 venture firm with a dedicated Bio + Health franchise investing across therapeutics, digital health, and TechBio. Recurring Alix co-investor in companies like Elegen and endpoint-health adjacent deals; operates at materially larger fund and check sizes.
  • ARCH Venture Partners: Pioneering Life Sciences and physical sciences venture firm founding and building companies from inception. Represents the large, established end of the Life Sciences VC market where Alix portfolio companies graduate for Series B and beyond.

Regional players

  • Liquid 2 Ventures: Early-stage venture firm (founded by Joe Montana) where Alix founder Chas Pulido began his HC/LS investing career. Strong US focus on healthcare and consumer, with a similar pre-seed/seed orientation and overlapping founder-network reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Alix Ventures social profiles

Digital presence

Alix Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alix Ventures leadership team

Management profile

Number of profiles

Profiles6 records

Alix Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alix Ventures M&A and investment

M&A and investment

M&A

Investments19 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alix Ventures

What does Alix Ventures do?

Alix Ventures provides Pre-Seed, Seed, and selective Series A equity investments ($100K–$500K initial checks) to early-stage Life Science and TechBio startups, reserving 50% of fund capital for follow-on participation in $1–2M Series A and $5–10M Series B SPVs. Portfolio companies receive value-add services including customer introductions, fundraising support, hiring assistance, KPI guidance, and access to the BIOS ecosystem (BIOS Commons community of 1000+ members, BIOS Angels syndicate, BIOS Medium, BIOS Podcast, BIOS Daily Newsletter with 25K+ subscribers) along with operating support from a 5x CEO Operating Partner.

Is Alix Ventures a public or private company?

Alix Ventures is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alix Ventures founded?

Alix Ventures was founded in 2019. It employs 1 to 10 people.

Where is Alix Ventures based?

Alix Ventures is headquartered in San Francisco, United States, in the North America region.

How does Alix Ventures make money?

One revenue line is on record: venture Capital Returns / Portfolio Equity.

Who are Alix Ventures's main competitors?

Direct peers on record are KdT Ventures, Civilization Ventures, Lifeforce Capital, Prime Movers Lab, Cantos Ventures and Pioneer Fund. Broad incumbents are Lux Capital, Andreessen Horowitz (a16z Bio + Health) and ARCH Venture Partners. Liquid 2 Ventures is listed as a regional player.

Does Alix Ventures have an API?

No public API is recorded for Alix Ventures.

What industry is Alix Ventures in?

Alix Ventures's product category is Life Science Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales